Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
E: phak@novonordisk.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,631.50 | 42.70 | 0.50% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,309.82 | 706.75 | 1.70% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,381.99 | 99.66 | 0.43% |
| NASDAQ | 19,158.48 | 421.27 | 2.25% |
| Nikkei 225 | 37,724.11 | 192.58 | 0.51% |
| NZX 50 Index | 12,582.33 | 35.11 | 0.28% |
| S&P 500 | 5,914.66 | 111.84 | 1.93% |
| S&P/ASX 200 | 8,407.60 | 46.60 | 0.56% |
| SSE Composite Index | 3,340.69 | 6.15 | -0.18% |